FMR CORP 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-07 10:23 am Sale |
2025-01-31 | 13G | Keros Therapeutics, Inc. KROS |
FMR CORP | 704,472 1.700% |
-3,169,732 (-81.82%) |
Filing |
| 2024-02-09 09:16 am Purchase |
2024-02-08 | 13G | Keros Therapeutics, Inc. KROS |
FMR CORP | 3,874,204 12.931% |
195,115 (+5.30%) |
Filing |
| 2023-02-09 12:48 pm Purchase |
2023-02-09 | 13G | Keros Therapeutics, Inc. KROS |
FMR CORP | 3,679,089 13.357% |
174,291 (+4.97%) |
Filing |
| 2022-02-09 09:22 am Purchase |
2022-02-08 | 13G | Keros Therapeutics, Inc. KROS |
FMR CORP | 3,504,798 14.978% |
860,178 (+32.53%) |
Filing |
| 2021-02-08 10:25 am Sale |
2021-02-05 | 13G | Keros Therapeutics, Inc. KROS |
FMR CORP | 2,644,620 11.411% |
-381,261 (-12.60%) |
Filing |
| 2020-11-10 10:27 am Purchase |
2020-11-09 | 13G | Keros Therapeutics, Inc. KROS |
FMR CORP | 3,025,881 14.999% |
3,025,881 (New Position) |
Filing |